Skip to main content

Table 5 Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. [10], assuming a five-year dwell time

From: Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia

Strategy Cost ($) Incremental changes in cost ($) Effectiveness (LYG) Incremental changes in effectiveness (LYG) Average cost-effectiveness ratio ($) Incremental cost-effectiveness ratio ($)
  (a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING PRACTICE 0   0   (Undefined)  
DCBE3 307,911,416 307,911,416 6,184 6,184 49,792 49,792
FOBT1+DBCE3 424,911,339 116,999,923 7,020 836 60,529 139,952
  1. Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion.